<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000560963">
  <TermName>recombinant vaccinia-CEA-MUC-1-TRICOM vaccine</TermName>
  <TermPronunciation>(ree-KOM-bih-nunt vak-SIH-nee-uh … vak-SEEN)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A cancer vaccine made with a form of vaccinia virus that does not cause disease in humans. It is being studied in the treatment of some types of cancer. The virus is changed in the laboratory to make human proteins, including the tumor markers called CEA and MUC-1, that may help immune cells in the body kill tumor cells. Also called inalimarev and PANVAC-V.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000721186" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;recombinant vaccinia-CEA-MUC-1-TRICOM vaccine&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000721185" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;vacuna de ACE-MUC-1-TRICOM recombinante de vaccinia&quot;" language="es" id="_4"/>
  <SpanishTermName>vacuna de ACE-MUC-1-TRICOM recombinante de vaccinia</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Vacuna contra el cáncer elaborada con una forma de virus de vaccinia que no causa enfermedad en seres humanos. Está en estudio para el tratamiento de algunos tipos de cáncer. El virus se altera en el laboratorio para hacer proteínas humanas, como los marcadores tumorales llamados ACE y MUC-1, que pueden ayudar a las células inmunitarias del cuerpo a destruir las células tumorales. También se llama inalimarev y PANVAC-V.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2008-03-10</DateFirstPublished>
</GlossaryTerm>
